The document discusses two studies, one on the safety and efficacy of risperidone long-acting injection in elderly patients with schizophrenia, and another on olanzapine orally disintegrating tablets in treating acutely ill non-compliant patients with schizophrenia.
The document discusses two studies, one on the safety and efficacy of risperidone long-acting injection in elderly patients with schizophrenia, and another on olanzapine orally disintegrating tablets in treating acutely ill non-compliant patients with schizophrenia.
The document discusses two studies, one on the safety and efficacy of risperidone long-acting injection in elderly patients with schizophrenia, and another on olanzapine orally disintegrating tablets in treating acutely ill non-compliant patients with schizophrenia.
The document discusses two studies, one on the safety and efficacy of risperidone long-acting injection in elderly patients with schizophrenia, and another on olanzapine orally disintegrating tablets in treating acutely ill non-compliant patients with schizophrenia.
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1of 1
Cataln R, Penads R.
Risperidone Long-Acting Injection: Safety and Efficacy in
Elderly Patients with Schizophrenia. Journal of Central Nervous System Disease 2011; 3: 95105 1. Kinon BJ, Hill AL, Liu H, Walker SK. Ollanzapine Orally Disintegrating Tablets in The Treatment of Acutely III No-compliant Patient with Schizophrenia. International Journal of Neurophysicpharmacology. 2003; 6: 97-102.
Remission in Schizophrenia: One-Year Italian Prospective Study of Risperidone Long-Acting Injectable (RLAI) in Patients With Schizophrenia or Schizoaffective Disorder